甲状腺癌
医学
甲状腺乳突癌
肿瘤科
优势比
癌症
单核苷酸多态性
内科学
多因子降维法
甲状腺
人口
遗传倾向
基因型
遗传学
生物
疾病
基因
环境卫生
作者
Hao Run-mei,Peng Han,Ling Zhang,Ying Bi,Jinfeng Yan,Honghui Li,Yanxia Bai,Chongwen Xu,Baiya Li,Huajing Li
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-11-08
卷期号:17 (34): 4677-4686
被引量:7
标识
DOI:10.2217/fon-2021-0748
摘要
Background: Thyroid cancer is the most common endocrine malignancy and the fastest growing cancer worldwide. Thyroid cancer has the largest genetic component of all cancers. Previous genome-wide association studies indicated that genetic polymorphism in PCNXL2 is related to thyroid cancer susceptibility in European populations. This study aims to determine the influence of PCNXL2 polymorphisms on thyroid cancer risk in Chinese individuals. Methods: This case-control study identified four polymorphisms in PCNXL2 among 510 thyroid cancer cases and 509 healthy controls. The associations of PCNXL2 polymorphisms with thyroid cancer susceptibility were detected by calculating odds ratios. Multifactor dimensionality reduction was performed to detect the impact of SNP (single nucleotide polymorphism)-SNP interactions on the risk of thyroid cancer. Results: The study showed that rs10910660 in PCNXL2 was related to thyroid cancer susceptibility. Rs12129938 played a protective role in thyroid cancer susceptibility. Stratification analysis indicated that rs10910660 increased thyroid cancer risk at age >45 years. Rs12129938 enhanced susceptibility to thyroid cancer at age >45 years, while this SNP decreased thyroid cancer risk at age ≤45 years. Rs4649295 was associated with lower susceptibility to thyroid cancer at age ≤45 years. An association was observed between rs6424270 and rs12129938 with decreased susceptibility to thyroid cancer in women. Rs10910660 was related to thyroid cancer risk in men. The combination of rs6424270, rs10910660, rs12129938 and rs4649295 was the best model to predict thyroid cancer. Conclusion: This study suggests that PCNXL2 polymorphisms are risk factors for thyroid cancer in the Chinese population.
科研通智能强力驱动
Strongly Powered by AbleSci AI